Nitrendipine

證據等級: L5

預測適應症: 4 個

Nitrendipine: From Hypertension to Migraine Disorder

One-Sentence Summary

Nitrendipine is a second-generation dihydropyridine (DHP) calcium channel blocker (CCB) used in the treatment of mild to moderate hypertension. The TxGNN model predicts it may be effective for migraine disorder (top-ranked prediction, score 99.42%), with 0 clinical trials and 3 publications supporting this direction. This is a multi-indication evaluation: additional predictions include pulmonary hypertension (L3 evidence, Proceed with Guardrails) and Prinzmetal angina (L3 evidence, Proceed with Guardrails), both carrying substantially stronger mechanistic and clinical support.

Quick Overview

Item	Content
Original Indication	Mild to moderate hypertension
Predicted New Indication	Migraine Disorder (Rank #1 of 4 predicted)
TxGNN Prediction Score	99.42%
Evidence Level	L4 (migraine disorder); L3 (pulmonary hypertension, Prinzmetal angina); L5 (migraine with brainstem aura)
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold (migraine disorder) / Proceed with Guardrails (pulmonary hypertension, Prinzmetal angina)

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data from DrugBank is not available for nitrendipine (Data Gap DG002). Based on pharmacological target data and published literature, nitrendipine is a synthetic 1,4-dihydropyridine CCB with high vascular selectivity. It exerts its primary effects by blocking L-type voltage-gated calcium channels (Cav1.1–Cav1.4) in vascular smooth muscle cells, reducing transmembrane calcium influx and producing arterial vasodilation. Pharmacological binding data also confirms activity at KCa3.1 (intermediate-conductance calcium-activated potassium channel, KCNN4 gene), which may further contribute to vascular tone regulation. This mechanism forms the proven basis for its use in hypertension.

For migraine disorder (Rank #1), the prediction is mechanistically plausible because cortical spreading depression (CSD) — the neurophysiological correlate of migraine aura — depends critically on transient, excess transmembrane calcium influx, and intracranial vascular dysregulation is a core feature of migraine attacks. The CCB class has well-established precedents in this space: flunarizine (non-selective CCB) carries Level A guideline recommendation for migraine prophylaxis (IHS/EAN), and verapamil is standard of care for cluster headache prevention. However, nitrendipine’s defining characteristic — high peripheral vascular selectivity — is precisely the property that raises uncertainty about migraine efficacy. Whether peripheral vasomodulation alone is sufficient to suppress CSD, without meaningful CNS penetration, remains unproven. The three available publications are limited to general DHP pharmacology reviews and a single abdominal migraine case report.

For pulmonary hypertension (Rank #3) and Prinzmetal angina (Rank #4), the mechanistic connection to nitrendipine’s known pharmacology is far more direct and better evidenced. Pulmonary arterial smooth muscle contraction is highly L-type calcium channel-dependent; CCB blockade measurably reduces pulmonary vascular resistance (PVR) and right ventricular afterload, with multiple small human hemodynamic studies specifically using nitrendipine confirming this. Per 2022 ESC/ERS PAH guidelines, high-dose CCBs are first-line therapy for vasoreactive PAH patients. Variant (Prinzmetal) angina is caused by focal coronary arterial spasm driven by aberrant calcium-mediated smooth muscle contraction — DHP-CCBs are guideline-recommended first-line agents (2023 ESC Chronic Coronary Syndrome guidelines), and one direct Japanese clinical study (n=21) demonstrated significant reduction in nitrendipine-treated anginal attack frequency from 2.1 to 0.7 per day.

Clinical Trial Evidence

Migraine Disorder (Rank #1)

No clinical trials specifically investigating nitrendipine for migraine disorder are currently registered.

Pulmonary Hypertension (Rank #3)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04330300	Phase 4	Suspended	2,414	COVID-19 ACEi/ARB investigation — not relevant to nitrendipine in PAH; trial suspended; classified as Grade C (database keyword mismatch on “pulmonary hypertension”)

Note: The single retrieved trial is not directly applicable. No dedicated nitrendipine PAH trials are registered.

Prinzmetal Angina (Rank #4)

No clinical trials specifically investigating nitrendipine for Prinzmetal/vasospastic angina are currently registered.

Literature Evidence

Migraine Disorder (Rank #1) — 3 Publications

PMID	Year	Type	Journal	Key Findings
9760558	1998	Case Series	Neurol Neurochir Pol	35-year-old woman with abdominal migraine (nocturnal attacks with nausea, vomiting, transient loss of consciousness) — nitrendipine treatment noted; attacks resolved
3319491	1987	Pharmacology Review	Drugs	Review of five second-generation DHP-CCBs including nitrendipine; documents greater vascular selectivity vs. nifedipine and discussion of wider clinical utility beyond hypertension
15449971	2004	Review	Am J Cardiovasc Drugs	Grapefruit juice interactions with cardiovascular drugs including nitrendipine; irreversible CYP3A4 inactivation significantly increases oral bioavailability — relevant pharmacokinetic safety context

Pulmonary Hypertension (Rank #3) — Top 10 of 20 Publications

PMID	Year	Type	Journal	Key Findings
2013178	1991	Prospective Clinical Study	Clin Cardiol	11 PAH patients with pulmonary fibrosis: sublingual nitrendipine 5 mg significantly reduced mean PAP from 32 to 29 mmHg at rest and from 55 to 49 mmHg during exercise
2468866	1988	Acute Hemodynamic Study	J Cardiovasc Pharmacol	10 PAH patients: sublingual nitrendipine reduced systemic BP, right atrial pressure, and improved cardiac output; some reduction in arterial oxygenation noted as a concern
1339619	1992	Comparative Study	Chin J Tuberc Respir Dis	Nitrendipine IV (100 µg/kg) significantly lowered PAP in pigs with acute hypoxic PAH; effect comparable to captopril
2937355	1986	Animal Study	Am Rev Respir Dis	Nitrendipine pretreatment in rats attenuated pulmonary vascular remodeling and right ventricular hypertrophy induced by 30-day intermittent hypobaric hypoxia
7712585	1994	Animal Study	Chin J Tuberc Respir Dis	Nitrendipine and nifedipine both prevented chronic hypoxic PAH and right ventricular hypertrophy in rats; preventive effect comparable to L-arginine (NO precursor)
8762482	1995	Animal Study	Chin J Tuberc Respir Dis	Nitrendipine IV significantly reduced PAP in pig hypoxic PAH model; study examined role of endothelin in PAH development alongside CCB treatment
2468868	1988	Clinical Study	J Cardiovasc Pharmacol	25 patients with angina + hypertension: nitrendipine 20 mg reduced aortic pressure, pulmonary wedge pressure, and ischemia burden; supports hemodynamic pleiotropic effects
3154329	1988	Review	Cardiovasc Drugs Ther	Comprehensive CCB review; states calcium antagonists are drugs of choice for pulmonary, coronary, cerebral, and mesenteric artery spasms — class framework for nitrendipine
3049099	1988	Review	Eur Heart J	Mechanistic review confirming that CCBs act against all vasoconstrictor/spastic responses in pulmonary, cerebral, mesenteric, and renal arteries
2693846	1989	Review	Magnesium	Pharmacological basis for CCB use; confirms nitrendipine’s inhibition of Ca²⁺ entry into vascular smooth muscle as primary antihypertensive and vasodilatory mechanism

Prinzmetal Angina (Rank #4) — 5 Publications

PMID	Year	Type	Journal	Key Findings
1920816	1991	Clinical Study	Jpn Heart J	Direct nitrendipine study: single-blind, n=21 variant angina patients; anginal attack frequency reduced significantly from 2.1 ± 0.3 to 0.7 per day at 10–20 mg/day; Holter ECG improvements confirmed
3345765	1988	Clinical Observation	Eur Heart J	Patient with Prinzmetal’s angina showing intermittent ST elevation during exercise — characterises the coronary vasospasm mechanism directly targeted by DHP-CCBs
14689111	2003	Review	Herz	Differential CCB therapy review; explicitly addresses DHP-CCB use in vasospastic angina; discusses endothelial function improvement and coronary protection
7711361	1995	Drug Review	Drugs Aging	Review of nilvadipine; notes antihypertensive efficacy comparable to nitrendipine; discusses DHP class potential in cerebrovascular disease and angina
2909138	1989	Clinical Study	Am J Cardiol	Felodipine (DHP-CCB class) significantly reduced hyperventilation-induced ischemic attacks in variant angina — class-level evidence supporting DHP mechanism in coronary vasospasm

Migraine with Brainstem Aura (Rank #2, L5)

No clinical trials or publications are available. Theoretical mechanistic consideration only: posterior circulation vasospasm in this rare migraine subtype may theoretically respond to CCB vasodilation, but vasodilators require caution in basilar-type migraine to avoid hemodynamic complications (blood-flow steal). Decision: Hold.

India Market Information

Nitrendipine is not currently marketed in India. No CDSCO regulatory authorizations are on record, and no licensed products exist in the domestic market.

For reference, nitrendipine is available in select international markets under the following brand names: Bayotensin, Baypress, Bylotensin, Deiten, Nidrel, Nitrepin. These authorizations may serve as reference products for any future regulatory pathway in India.

Safety Considerations

Formal warnings and contraindications data are not available for the India market (Data Gap DG001 — Blocking severity). Please refer to the approved package insert from a jurisdiction where nitrendipine is licensed (e.g., Germany, European reference market).

Pharmacological Target Profile (from pharmacology database — reflects known binding activity, not drug-drug interactions):

Target	Gene	Species	Clinical Relevance
Cav1.2 (L-type Ca²⁺, α1C)	—	Dog	Primary smooth muscle/cardiac target; basis of vasodilatory effect
Cav1.3 (L-type Ca²⁺, α1D)	CACNA1D	Human	Cardiac and neuronal L-type channel; relevant to CNS activity questions
Cav1.4 (L-type Ca²⁺, α1F)	CACNA1F	Human	Retinal L-type channel; monitor for visual effects
Cav1.1 (L-type Ca²⁺, α1S)	Cacna1s	Rat	Skeletal muscle channel; lower clinical relevance at therapeutic doses
KCa3.1	KCNN4	Human	Intermediate-conductance K⁺ channel; may modulate vascular smooth muscle tone

Drug Interactions: No traditional drug-drug interaction data is available in the current evidence pack. CYP3A4 inhibition by grapefruit juice is documented to significantly increase nitrendipine bioavailability (PMID 15449971) — a relevant clinical consideration for dosing management.

Conclusion and Next Steps

Decision: Hold (migraine disorder) / Proceed with Guardrails (pulmonary hypertension, Prinzmetal angina)

Rationale:

For migraine disorder (top TxGNN rank): Despite a high model score (99.42%), the available evidence is insufficient to support clinical development. Only one case report and two pharmacology reviews exist, with no dedicated clinical trials. Nitrendipine’s high peripheral vascular selectivity and limited CNS penetration are unresolved concerns that distinguish it from guideline-supported CCBs in migraine prophylaxis (e.g., flunarizine, which has broader CNS activity). A Hold decision is appropriate until CNS pharmacokinetics and mechanistic studies are available.

For pulmonary hypertension: Multiple small prospective hemodynamic studies specifically in nitrendipine demonstrate measurable PAP reduction in PAH patients with pulmonary fibrosis, supported by animal model data on vascular remodeling prevention. Per 2022 ESC/ERS guidelines, high-dose CCBs are a validated first-line option in vasoreactive PAH — a patient-selection criterion that defines a clear, guardable pathway. Proceed with Guardrails.

For Prinzmetal (vasospastic) angina: One direct Japanese clinical study (n=21) demonstrated significant efficacy with nitrendipine 10–20 mg/day, and DHP-CCBs are guideline-recommended first-line agents for this indication. The primary gap is the absence of India regulatory approval. Proceed with Guardrails.

To proceed, the following is needed:

DG001 remediation (Blocking): Download and parse the package insert from a jurisdiction where nitrendipine is approved (Germany or Japan) to obtain full warnings, contraindications, and precaution data
DG002 remediation (High): Query DrugBank API for complete MOA data, particularly CNS penetration characteristics, to resolve the migraine indication uncertainty
For migraine disorder: Commission a systematic review of all DHP-CCBs in migraine prophylaxis, with CNS penetration as a stratification variable; use nimodipine (CNS-penetrant DHP) as a mechanistic benchmark
For pulmonary hypertension: Design patient eligibility criteria around acute vasoreactivity testing (per ESC/ERS 2022); confirm nitrendipine formulation availability in India or identify manufacturing pathway
For Prinzmetal angina: Initiate CDSCO regulatory pathway assessment; evaluate feasibility of a bridging study using the existing Japanese clinical data (PMID 1920816) as the primary evidence anchor
Comparative positioning analysis of nitrendipine vs. commonly available CCBs in India (amlodipine, diltiazem) to establish clinical differentiation and competitive rationale
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.